Latest Conference Articles

Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses early efficacy and safety of QTX3034 plus cetuximab with or without mFOLFOX6 in KRAS G12D–mutant CRC.

Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.

Doris Hansen, MD, discusses the potential role of GPRC5D-directed CAR T-cell therapy with arlo-cel in patients with multiple myeloma.

First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.

IBI363 plus bevacizumab extended progression-free survival vs docetaxel in patients with immunotherapy-resistant lung adenocarcinoma in a randomized phase 1b study.

Prior immune checkpoint inhibitor exposure raised mucocutaneous adverse effect risk, particularly dermatitis, with lirafugratinib in FGFR2-altered tumors.

Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.

Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.

INCB161734 plus chemotherapy was tolerable and elicited responses in updated data from a trial of patients with KRAS G12D–mutated pancreatic cancer.

Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.

Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.

Izalontamab brengitecan improved progression-free survival vs chemotherapy in EGFR-mutated lung cancer after a third-generation EGFR inhibitor.

Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.

KEYNOTE-412 ctDNA data tie early clearance to longer survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.

Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.

Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.

Risvutatug rezetecan delayed progression vs gemcitabine and docetaxel in patients with osteosarcoma after 2 or more prior systemic therapies.

Paul L. Swiecicki, MD, discusses first-line amivantamab plus pembrolizumab and carboplatin in recurrent/metastatic head and neck cancer.

Georgina V. Long, AO, BSc, PhD, MBBS, discusses phase 3 INTerpath-001 data for adjuvant intismeran autogene plus pembrolizumab in melanoma.

Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.

Updated FONTANA data show torvu-sam activity across FRα expression levels in platinum-resistant ovarian cancer.

In HARMONi-GI1, ivonescimab plus chemotherapy extended survival over durvalumab plus chemotherapy in untreated advanced biliary tract cancer.

Dana M. Chase, MD, discusses updated BEHOLD-1 data for mocertatug rezetecan and where B7-H4–targeted ADCs may fit in platinum-resistant ovarian cancer.

Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.

Divarasib extended survival over first-generation KRAS G12C inhibitors in a head-to-head phase 3 trial in previously treated lung cancer.

In SAFFRON, the oral EGFR/MET inhibitor pairing extended survival over platinum/pemetrexed in MET-driven lung cancer that progressed on osimertinib.

Tovecimig plus paclitaxel improved objective response over paclitaxel alone in previously treated advanced biliary tract cancer in COMPANION-002.

Adding LK101 to tislelizumab-based first-line maintenance yielded early antitumor activity and signs of immune activation in advanced NSCLC.